Brentuximab vedotin for CD30-positive tumours

Masuda, Shigeo; Miyagawa, Shigeru; Nakamura, Toshiharu; Khurram, Maaz Asher; Sawa, Yoshiki

doi:10.1016/s1470-2045(16)30404-1

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the cut-off of the CD30-positive rate for treating ENKTL in using brentuximab vedotin has been ambiguous and need to be investigated. Lots of aspects might contribute to the anti-CD30 therapy, such as the mechanism anti-CD30 of ENKTL and bystander killing phenomenon (neighborhood cells which are negative in CD30 surrounding the CD30 positive tumor cells also be killed since the CD30 positive neoplastic cells secret CD30-expressing extracellular vesicles binding to CD30 ligands on bystander cells) [ 39 , 40 ]. In addition, for patients with low CD30-positive rate ENKTL, epigenetic therapy with drugs like vorinostat and cladribine could be applied to induce the CD30 expression in neoplastic cells before treating with anti-CD30 antibody in order to achieve a better outcome [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis

et al. 2018

View full text Add to dashboard Cite

BackgroundThe paradoxical reports about the prognostic value of the CD30 expression in extranodal NK/T-cell lymphoma (ENKTL) have restricted its further applications in clinical practice. To identify the common effects and the variation, we conducted this systematic review and meta-analysis.MethodsPubMed, MEDLINE, Embase, and Web of Science were searched between January 1975 and 31 January 2017. The pooled hazard ratio was used to estimate the effect of the CD30 expression on overall survival. Bias was assessed by prespecified criteria referring to Reporting Recommendations for Tumor Marker Prognostic Studies and Newcastle-Ottawa Scale.ResultsTen retrospective cohort studies with 310 patients are included. CD30 is associated with better overall survival significantly (HR 0.71, 95% CI 0.51 to 0.99, I2 = 0%). A greater effect is observed among studies including participants predominant in regional involvement (HR 0.31, 95%CI 0.13 to 0.76, I2 = 0%) compared with those in systemic involvement.ConclusionsThis study indicates that the CD30 expression is significantly associated with better prognosis in ENKTL, especially for patients with regional lymphoma involvement.

show abstract

Section: Discussionmentioning

confidence: 99%

CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

Current targeted therapies in lymphomas

Chung

2019

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Purpose This article summarizes current targeted therapies that have received regulatory approval for the treatment of B- and T-cell lymphomas. Summary Over the last 20 years, new drug therapies for lymphomas of B cells and T cells have expanded considerably. Targeted therapies for B-cell lymphomas include: (1) monoclonal antibodies directed at the CD20 lymphocyte antigen, examples of which are rituximab, ofatumumab, and obinutuzumab; (2) gene transfer therapy, an example of which is chimeric antigen receptor–modified T-cell (CAR-T) therapy directed at the CD19 antigen expressed on the cell surface of both immature and mature B cells; and (3) small-molecule inhibitors (ibrutinib, acalabrutinib, copanlisib, duvelisib, and idelalisib) that target the B-cell receptor signaling pathway. Of note, brentuximab vedotin is an antibody–drug conjugate that targets CD30, another lymphocyte antigen expressed on the cell surface of both Hodgkin lymphoma (a variant of B-cell lymphoma) and some T-cell lymphomas. Although aberrant epigenetic signaling pathways are present in both B- and T-cell lymphomas, epigenetic inhibitors (examples include belinostat, vorinostat, and romidepsin) are currently approved by the Food and Drug Administration for T-cell lymphomas only. In addition, therapies that target the tumor microenvironment have been developed. Examples include mogamulizumab, bortezomib, lenalidomide, nivolumab, and pembrolizumab. In summary, the efficacy of these agents has led to the development of supportive care to mitigate adverse effects, due to the presence of on- or off-target toxicities. Conclusion The therapeutic landscape of lymphomas has continued to evolve. In turn, the efficacy of these agents has led to the development of supportive care to mitigate adverse effects, due to the presence of on- or off-target toxicities. Further opportunities are warranted to identify patients who are most likely to achieve durable response and reduce the risk of disease progression. Ongoing trials with current and investigational agents may further elucidate their place in therapy and therapeutic benefits.

show abstract

Histologic, Phenotypic, and Molecular Characterization of Feline Hodgkin‐Like Lymphoma With Classical Reed‐Sternberg Cells

Marconato,

Maga,

Iussich

et al. 2024

Vet Comparative Oncology

View full text Add to dashboard Cite

Hodgkin‐like lymphoma (HLL) is a rare neoplasm in cats that shares characteristics with the human disease. The hallmark of HLL is the presence of Reed‐Sternberg (RS) cells expressing CD30 and CD20. This study aimed to elucidate the clinicopathologic features, immunophenotype and clonality patterns of feline HLL. A comprehensive retrospective review of clinicopathologic and molecular data of nodal lymphomas over a 6‐year period was conducted in MyLav laboratory. Twenty‐four cases were identified. All cats presented with submandibular or retropharyngeal lymphadenopathy. Histopathologic examination revealed a multifocal to diffuse proliferation of medium‐to‐large lymphoid cells with low mitotic activity, interspersed RS cells, and a heterogeneous inflammatory infiltrate comprising T‐cells, plasma cells and neutrophils. In addition, extensive necrosis was a consistent finding. Immunohistochemistry showed a variable membranous CD20 and nuclear PAX5 expression in neoplastic cells, while RS cells displayed only mild to moderate CD20 positivity and were negative to PAX5. In 21/24 cases (87.5%), RS cells were diffusely CD30‐positive. PARR analysis demonstrated clonal B‐cell expansion in 60% of cases, with the remaining 40% exhibiting polyclonality. For the 10 cats with available follow‐up, the prognosis was generally favourable, with only two cats succumbing to progressive disease. In conclusion, diagnosing feline HLL is challenging. The expression of CD30 and CD20 by RS cells should be considered a hallmark of the disease, but only after excluding differential diagnoses such as anaplastic B‐cell lymphoma and granulomatous lymphadenopathy.

show abstract

Brentuximab vedotin for CD30-positive tumours

Cited by 3 publications

References 5 publications

CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis

CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis

Current targeted therapies in lymphomas

Histologic, Phenotypic, and Molecular Characterization of Feline Hodgkin‐Like Lymphoma With Classical Reed‐Sternberg Cells

Contact Info

Product

Resources

About